about
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneBroadening the repertoire of melanoma-associated T-cell epitopes.Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.Cellular based cancer vaccines: type 1 polarization of dendritic cells.Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.High frequency of T cells specific for cryptic epitopes in melanoma patientsSpontaneous presence of FOXO3-specific T cells in cancer patients.Immunobiological effects of glucosamine in vitro.Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems.The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.In-chip fabrication of free-form 3D constructs for directed cell migration analysis.Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21.Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells.T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression.Frequent adaptive immune responses against arginase-1.Immune Monitoring Using mRNA-Transfected Dendritic Cells.Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.Special AT rich-binding1 protein (SATB1) in malignant T cells.The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signalingPrinciples of adoptive T cell therapy in cancerTransfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer PatientsCell culture plastics with immobilized interleukin-4 for monocyte differentiationStudies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic PotentialComparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patientsHigh immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancerAdoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot studyT cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patientsChemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse modelMERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
P50
Q28553703-1A6881E7-183E-4085-ACDC-6CD78C180AEDQ35546276-3FDED803-06C9-4D00-A737-FF2B63D74179Q36444798-36AA0A63-F2F3-4F74-891B-82BDAFCAF1A2Q38029745-78D2C621-C3E2-4B8D-8CCC-E461C135D7FFQ38394457-2A38DDED-6EBB-42BF-945E-D85107DEFCFFQ38871209-8801D0CC-C289-4123-8514-4BCBEE85BE1DQ40994145-0FB1C815-EBB5-4E00-9A8B-7AA0663E6103Q41297982-6C84DCD0-F3C9-4360-A000-34173F4FE213Q41662222-34448B03-540E-43A4-8D36-C7EB41D58E52Q42141424-AB01F57B-818A-45E7-A6F4-B81442B7953FQ43196241-69D2FE5F-4890-48B3-BD7C-87C3B5462D68Q44594889-14B49412-A141-4578-BFF0-717709AD959DQ47841318-475BCD87-9CBF-41BC-AE04-617E83C069CEQ48178961-134F6B54-B77E-4A7A-B363-3EBE530DC646Q48289524-B1D3E36B-FC5A-4FE7-B1FB-5E0CD26CEAF2Q50187924-248D463D-3E4E-4B87-B116-AA83F2A6B811Q50227164-54B8CD3C-8050-498C-8C1F-C3BF9C7EC693Q50545414-AFC389FB-E9F6-4ADB-8842-FB5E6F093DF1Q51527190-E494540C-73F2-4039-BC07-E644F3DF7AAAQ51637013-BC6A2E52-97A4-4CD1-8F95-4B82397E3D6DQ51675549-A1633D34-E675-4C20-901C-AABFBA84AA68Q52567363-5AFDDC9E-5380-4B88-95AA-C62C4E8ABE04Q52733766-7C903178-AC82-4002-98DB-BBC54E00B13DQ53092562-90F9DBD0-B5AE-46FA-9E6C-A6BE7365848FQ53550817-15029EE9-F0FA-43D6-AEE5-A4C590C9D589Q53750249-2FEAB42E-3900-4596-AA71-837498441A67Q54965630-DC7009B0-E867-4654-AD6C-848E3848D4F0Q54979277-498B8229-8B99-4A02-8107-E9CF41DC7B26Q56902415-60030746-1922-425B-8E17-CD45CD0E590EQ61698755-87D78BB2-2DD4-44E6-9069-50198DECD0ABQ61698775-05201E25-B8BE-4544-97FD-834E670954EFQ61698794-6AF99924-3A81-42E4-BE5A-328DD89368AFQ61698821-8E12EC48-C31F-4072-A963-E14462E7E733Q61698862-3D398141-FDD6-40F4-88AA-28C6891D4AA0Q61698866-CB582281-E327-49DA-9928-0DF8C00DCA44Q83903378-8342B9D3-932E-4F49-B5D9-1EC6E4775026Q90326770-FBA3F7C3-2E17-4838-9E0F-137733A53719Q91333564-BAAA8DDE-0AE4-4E12-92CC-1348EE0DA075Q91473748-15ADAE3D-816A-4CF7-BCFE-350E76B79854Q91563227-192689E0-7425-4BF7-AF8B-C118BD012B69
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Özcan Met
@ast
Özcan Met
@en
Özcan Met
@es
Özcan Met
@nl
Özcan Met
@sl
type
label
Özcan Met
@ast
Özcan Met
@en
Özcan Met
@es
Özcan Met
@nl
Özcan Met
@sl
prefLabel
Özcan Met
@ast
Özcan Met
@en
Özcan Met
@es
Özcan Met
@nl
Özcan Met
@sl
P1053
T-1006-2017
P106
P1153
55914122000
P31
P3829
P3835
ozcan-met2
P496
0000-0002-3256-7592